A study of 421,402 people found that those taking cholesterol-lowering statins were 15% less likely to develop glaucoma. Among people who already had it, the bigger difference was in who needed surgery.
Statins are among the most prescribed drugs in the world, taken by millions of people for one reason: to lower cholesterol. But for years, lab studies have hinted that they might also protect nerve cells from dying, including the ones that connect the eye to the brain. US researchers decided to check that in real patients, using medical records from a global database of 165 million people. They focused on glaucoma, the eye disease that slowly and silently steals sight.
People who took statins were less likely to develop open-angle glaucoma, the most common form. Over five years, 2.3% of statin users were diagnosed with it, compared with 2.6% of a matched group who did not take statins. That works out to a 15% lower risk, and the gap was still about 10% after ten years.
The difference per person is small. But the link between statins and glaucoma looked stronger in people who already had the disease, which is the part most likely to matter to patients.
Among nearly 30,000 people with glaucoma who took statins, compared with the same number who did not, statin users were less likely to need their treatment stepped up. Over five years, they had a 36% lower risk of conventional glaucoma surgery, a 55% lower risk of minimally invasive surgery, and a 60% lower risk of laser treatment. They were also less likely to need extra eye drops.
The idea is not new. A 2012 study of more than 500,000 people in Ophthalmology found that people with high cholesterol who took statins for two years or longer had a modestly lower risk of developing open-angle glaucoma. The researchers behind the new study note that statins’ possible role in preventing or slowing glaucoma has remained poorly understood, which is why they went back to a much larger dataset.
Glaucoma damages the optic nerve, usually without pain or early symptoms, and it is a leading cause of irreversible blindness. Treatment can slow it but cannot reverse the damage, so anything that protects the nerve early would matter.
For the main analysis, the team compared 210,701 people over 40 who had a record of statin use between 2006 and 2026 with a matched group of 210,701 people who did not. Everyone included had to have had at least one eye examination on record, so both groups were being watched for eye disease.
The second finding is about which statin. The pattern held for people taking atorvastatin or rosuvastatin, two of the most common and more potent statins. People taking only simvastatin or pravastatin did not show a significantly lower risk of developing glaucoma or needing conventional surgery, although they did show less laser treatment and minimally invasive surgery. The researchers say this may simply reflect the smaller numbers of people on those drugs.
How statins might help the eye is still unclear. Beyond lowering cholesterol, lab studies suggest they may protect nerve cells from dying, and the optic nerve is made of exactly that kind of cell.
For anyone already taking a statin, the findings are a possible bonus, not a reason to start one. If you take statins and have a family history of glaucoma, regular eye checks still matter, because the disease rarely causes symptoms until vision is already lost. Researchers are exploring other ways to protect the same cells, including an approach we covered earlier that targets their energy supply.
There are limits to what this shows. The study is observational and based on medical records, so it cannot prove that statins prevent glaucoma. People who take statins may differ from those who do not in ways the matching could not capture, such as how often they see doctors or how carefully they manage their health.
Records show that a statin was prescribed, not whether people took it every day or at what dose. The researchers say randomized trials are now needed to confirm whether statins protect against glaucoma and to work out which patients might benefit.
Source
Lin F, et al. “Statin use is associated with lower risk of open-angle glaucoma incidence and treatment escalation.” British Journal of Ophthalmology, 2026.
DOI: 10.1136/bjo-2026-330339
Also cited
Stein JD, Newman-Casey PA, Talwar N, et al. “The relationship between statin use and open-angle glaucoma.” Ophthalmology, 2012.
DOI: 10.1016/j.ophtha.2012.04.019
